22.60
전일 마감가:
$24.04
열려 있는:
$24.1
하루 거래량:
2.09M
Relative Volume:
2.14
시가총액:
$2.31B
수익:
-
순이익/손실:
$-804.34M
주가수익비율:
-2.4017
EPS:
-9.41
순현금흐름:
$-531.06M
1주 성능:
-24.34%
1개월 성능:
-39.21%
6개월 성능:
-53.47%
1년 성능:
-56.59%
바이오헤이븐 Stock (BHVN) Company Profile
명칭
Biohaven Ltd
전화
203-404-0410
주소
215 CHURCH STREET, NEW HAVEN, CT
BHVN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BHVN
Biohaven Ltd
|
22.60 | 2.31B | 0 | -804.34M | -531.06M | -9.41 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.74 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
617.00 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
567.09 | 34.59B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
255.76 | 33.10B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
271.04 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오헤이븐 Stock (BHVN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-02-11 | 개시 | Deutsche Bank | Buy |
2024-09-16 | 개시 | Jefferies | Buy |
2024-09-04 | 개시 | Bernstein | Outperform |
2024-07-24 | 개시 | Morgan Stanley | Overweight |
2024-02-16 | 개시 | RBC Capital Mkts | Outperform |
2024-02-06 | 개시 | UBS | Buy |
2023-12-22 | 개시 | H.C. Wainwright | Buy |
2023-12-08 | 개시 | Robert W. Baird | Outperform |
2023-01-24 | 개시 | SVB Securities | Outperform |
2023-01-04 | 개시 | JP Morgan | Overweight |
2022-12-02 | 개시 | BTIG Research | Buy |
2022-10-26 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
2022-10-12 | 개시 | Piper Sandler | Overweight |
2022-08-19 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
2022-08-08 | 다운그레이드 | Wedbush | Outperform → Neutral |
2022-05-11 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
2021-10-19 | 재개 | Morgan Stanley | Equal-Weight |
2021-08-10 | 다운그레이드 | UBS | Buy → Neutral |
2021-08-03 | 재확인 | Canaccord Genuity | Buy |
2021-03-11 | 개시 | UBS | Buy |
2020-12-15 | 개시 | H.C. Wainwright | Buy |
2020-04-17 | 개시 | Cowen | Outperform |
2020-02-10 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2020-02-06 | 개시 | Mizuho | Buy |
2019-11-22 | 개시 | Wedbush | Outperform |
2019-06-25 | 재확인 | Canaccord Genuity | Buy |
2019-05-06 | 개시 | Goldman | Buy |
2019-04-09 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2019-03-04 | 재확인 | Needham | Buy |
2018-07-03 | 재확인 | Needham | Buy |
2018-07-02 | 재확인 | Needham | Buy |
2018-04-05 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2018-02-22 | 재확인 | Canaccord Genuity | Buy |
2017-12-15 | 개시 | Canaccord Genuity | Buy |
2017-10-03 | 재확인 | Needham | Buy |
모두보기
바이오헤이븐 주식(BHVN)의 최신 뉴스
American Century Companies boosts stake in Biohaven, ETF Daily News says - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven LtdBHVN - PR Newswire
Biohaven Ltd. Shares Tumble Amid Market Reassessment - TipRanks
Biohaven Ltd. (NYSE:BHVN) Shares Bought by American Century Companies Inc. - Defense World
Teacher Retirement System of Texas Raises Stake in Biohaven Ltd. (NYSE:BHVN) - Defense World
(BHVN) Proactive Strategies - Stock Traders Daily
Biohaven stock hits 52-week low at $26.7 amid market challenges By Investing.com - Investing.com South Africa
Biohaven stock hits 52-week low at $26.7 amid market challenges - Investing.com India
Biohaven (BHVN) Stock Price, News & Analysis - MarketBeat
Emerald Advisers LLC Acquires New Holdings in Biohaven Ltd. (NYSE:BHVN) - MarketBeat
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Amundi - Defense World
Major Player in the Multiple System Atrophy (MSA) Market - openPR
Multiple System Atrophy Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Ionis Pharma - Barchart
Multiple System Atrophy Market to Reach New Heights in Growth - openPR
Immunovant data positive for Biohaven, says Deutsche Bank - TipRanks
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biohaven Ltd. (BHVN) and Encourages Shareholders to Learn More About the Investigation - Markets Insider
How To Trade (BHVN) - Stock Traders Daily
Biohaven’s 47% decline validates InvestingPro’s bearish Fair Value call By Investing.com - Investing.com Australia
SEC Form DEF 14A filed by Biohaven Ltd. - Quantisnow
Spinocerebellar Ataxias Pipeline 2025: Therapies, MOA - openPR
Charles Schwab Investment Management Inc. Increases Stock Holdings in Biohaven Ltd. (NYSE:BHVN) - Defense World
Biohaven Ltd. Being Investigated on Behalf of Biohaven Ltd. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire
US Bancorp DE Raises Stock Position in Biohaven Ltd. (NYSE:BHVN) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biohaven Ltd. (BHVN) And Encourages Shareholders to Connect - Markets Insider
Biohaven Ltd. Under Investigation: Levi & Korsinsky Probes Potential Securities Violations - Apna Kal
Investors who lost money on Biohaven Ltd. should contact Levi & Korsinsky about an ongoing investigationBHVN - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Biohaven Ltd. (BHVN) And Encourages Investors to Connect - Markets Insider
Biohaven Ltd. (NYSE:BHVN) Shares Bought by Bank of New York Mellon Corp - Defense World
Unpartnered Obesity Assets Are Becoming Slim Pickings For Pharma - Citeline News & Insights
Bronstein, Gewirtz & Grossman, LLC Encourages Biohaven Ltd. (BHVN) Stockholders to Inquire about Securities Investigation - Markets Insider
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biohaven Ltd. (BHVN) and Encourages Investors to Learn More About the Investigation - Markets Insider
Biohaven Ltd. (NYSE:BHVN) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Biohaven Ltd. INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Biohaven Ltd. (BHVN) - ACCESS Newswire
Biohaven Ltd. (BHVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
ATTENTION Biohaven Ltd. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights - ACCESS Newswire
Positive Outlook for Biohaven Ltd. Amid Promising Developments and FDA Priority Review - TipRanks
Independent Director of Biohaven John Childs Buys More Stock - Simply Wall St
Biohaven Ltd. (BHVN): Among Stocks with Heavy Insider Buying in 2025 - Insider Monkey
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biohaven Ltd. (BHVN) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Biohaven Ltd. Investigated by Shareholder Rights AdvocatesInvestors Should Contact Levi & Korsinsky Regarding Potential Securities Law ViolationsBHVN - ACCESS Newswire
Morgan Stanley Lowers Biohaven (NYSE:BHVN) Price Target to $63.00 - Defense World
How to Take Advantage of moves in (BHVN) - Stock Traders Daily
Empowering women in STEM: Navigating CMC regulatory affairs -March 08, 2025 at 04:31 am EST - Marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages Biohaven Ltd. (BHVN) Investors to Inquire about Securities Investigation - markets.businessinsider.com
Biohaven price target lowered to $63 from $69 at Morgan Stanley - Yahoo Finance
Piper Sandler maintains Biohaven stock with $76 target - Investing.com India
Biohaven Ltd. (NYSE:BHVN) Shares Sold by Private Advisor Group LLC - Defense World
JPMorgan Chase & Co. Lowers Biohaven (NYSE:BHVN) Price Target to $68.00 - Defense World
Biohaven FY2025 EPS Forecast Reduced by Cantor Fitzgerald - Defense World
Morgan Stanley cuts Biohaven stock price target to $63 from $69 By Investing.com - Investing.com South Africa
바이오헤이븐 (BHVN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):